Has Neurocept's manufacturer changed ownership or been acquired recently (year 2023 2024)?

Executive Summary — Short answer and synthesis

The evidence indicates that Neurocept’s manufacturing ownership landscape did change in the 2023–2024 timeframe, but the record is fragmented and points to more than one corporate transaction involving different corporate parents. One 2023 filing documents Integer Holdings acquiring substantially all assets of InNeuroCo (the maker of Neurocept) effective October 1, 2023, while separate 2024 disclosures show Nihon Kohden acquiring a controlling stake in NeuroAdvanced Corp., the parent of Ad‑Tech Medical Instrument Corporation, described in some sources as linked to Neurocept manufacturing operations ^{[1] [2] [3]}. Several official product pages and company sites show no acquisition details, highlighting information gaps and potential branding or supplier complexity that require careful parsing ^{[4] [5]}.

1. What primary acquisition claims appear in the record — two distinct deals, one clear and one corporate-parent level

The clearest single-transaction claim is that Integer Holdings Corporation acquired substantially all assets and assumed certain liabilities of InNeuroCo, Inc. for $58 million, with an effective date of October 1, 2023; this is presented as a direct asset acquisition of the company identified as Neurocept’s manufacturer in one report ^[1]. Separately, Nihon Kohden announced in 2024 that it acquired 71.4% of NeuroAdvanced Corp., the parent of Ad‑Tech Medical Instrument Corporation, with a completion notice dated November 29, 2024 in related disclosures; several analyses treat Ad‑Tech/NeuroAdvanced as linked to Neurocept manufacturing or related intracranial electrode production ^{[2] [3]}. Both transactions are presented as ownership changes, but they reference different corporate entities tied to neurotechnology products, which indicates multiple corporate movements across 2023–2024 rather than a single simple sale ^{[1] [2]}.

2. Why sources differ — brand, supplier, and parent‑company complexity muddy the trail

Product listings and the official Neurocept website show no explicit disclosure of ownership changes or acquisition dates, which creates a gap between public product pages and transactional filings ^{[4] [5]}. The divergent documents reference InNeuroCo, NeuroAdvanced, Ad‑Tech, and parent companies like Integer Holdings or Nihon Kohden, suggesting that Neurocept’s manufacturing and marketing chain may involve multiple legal entities: a manufacturer, a brand marketer, and corporate parents that may be bought or sold separately. This corporate layering explains why one authoritative asset sale (InNeuroCo → Integer) can coexist with a separate parent‑company share acquisition (NeuroAdvanced → Nihon Kohden) without contradiction, yet still leave consumers and some public pages without unified messaging ^{[1] [2]}.

3. What the timelines say — acquisitions in 2023 and in late 2024 are both reported

The record documents an asset acquisition effective October 1, 2023 (Integer Holdings and InNeuroCo) and a share‑acquisition completed November 29, 2024 (Nihon Kohden and NeuroAdvanced/Ad‑Tech parent), establishing that ownership changes occurred across both 2023 and 2024, depending on which corporate entity you associate directly with Neurocept’s manufacture ^{[1] [2] [3]}. The differing dates map to separate corporate transactions rather than a single event; therefore, answering whether the manufacturer “changed ownership in 2023 or 2024” depends on identifying which named legal entity is the operative manufacturer for Neurocept at a given moment ^{[1] [3]}.

4. What remains uncertain — gaps, silence from product sites, and overlapping company names

Public product pages and an official brand site contain no corroboration of these transactions and do not clarify which legal entity now controls production, distribution, or intellectual property for Neurocept, leaving unresolved questions about operational control, continuity of manufacturing, and potential supply‑chain changes ^{[4] [5]}. The presence of multiple corporate names in filings and press notices raises ambiguity about whether Neurocept is tied to InNeuroCo, Ad‑Tech, NeuroAdvanced, or other related marketers, and whether any transaction directly transferred the Neurocept brand versus separate manufacturing assets ^{[1] [2]}. These omissions matter for product warranties, regulatory reporting, and consumer notifications.

5. Bottom line for verification and next steps — what a careful reader should do

The factual bottom line is that documents in the supplied analyses report acquisitions affecting firms linked to Neurocept in both 2023 and 2024, but the connection between each corporate transaction and the specific legal entity that currently manufactures Neurocept is not uniformly documented across sources ^{[1] [2] [3]}. To fully verify current ownership, obtain primary transaction filings (asset purchase agreements, SEC or investor‑relations notices), contact the product’s listed manufacturer for their official ownership statement, and review regulatory submissions where manufacturer identity is declared. The mixed record and silent product pages indicate further document retrieval is required to definitively map corporate ownership to the Neurocept product chain ^{[4] [5] [1] [2]}.